Plasmodium erythrocytic-stage parasite targets

Plasmodium erythrocytic-stage parasite targets refer to the collective group of proteins, enzymes, and biological processes within the malaria parasite that are active during its replication phase inside host red blood cells [1, 2]. This stage of the Plasmodium life cycle is responsible for the clinical manifestations of malaria, including fever, anemia, and organ failure [9, 10]. Prominent targets within this category include enzymes of the folate biosynthesis pathway, such as dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS), as well as the mitochondrial electron transport chain (Cytochrome b) [2, 3]. Additionally, the detoxification of heme into hemozoin is a critical process targeted by traditional antimalarials like chloroquine and quinine [3, 5]. Modern therapeutic strategies also focus on parasite-specific kinases, transporters like PfCRT, and the apicoplast organelle [4, 5]. While these targets are the foundation of current malaria treatment, the continuous evolution of parasite resistance to drugs like artemisinin and chloroquine necessitates the ongoing identification of novel erythrocytic-stage targets to maintain therapeutic efficacy [2, 8].

Other names

Blood-stage malaria targetsAsexual erythrocytic stage targetsPlasmodium blood-stage proteinsErythrocytic cycle targets

Inhibition of hemozoin formation, inhibition of folate biosynthesis, inhibition of mitochondrial electron transport, induction of oxidative stress via endoperoxide activation, and inhibition of protein synthesis.